Clinical Trial: Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome

Study Status: Terminated
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Terlipressin Given As I.V. Boluses Vs Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome (Hrs): Preliminary R

Brief Summary: It is well known that terlipressin and albumin improve renal function in patients with cirrhosis and type 1 HRS. In previous studies terlipressin has been used either as intravenous boluses moving from an initial dose of 0.5-1 mg/4 hr or as continuous intravenous infusion at the initial dose of 2 mg/24 h. Up to now the two schedules of i.v. administration of terlipressin have never been compared. Nevertheless, it has been hypothesized that continuous intravenous infusion assures a more steady profile of effect on portal pressure in patients with cirrhosis. Thus, the aim of the study will be to compare terlipressin given as i.v. bolus vs terlipressin given as continuous intravenous infusion in the treatment of type 1 HRS in patients with cirrhosis.

Detailed Summary:
Sponsor: University of Padova

Current Primary Outcome: The primary end-point of the study is the complete reform of the renal function (creatinine < 1.5 mg/dl). [ Time Frame: The treatment will be continued for a maximum of 15 days ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of Padova

Dates:
Date Received: August 26, 2008
Date Started: May 2005
Date Completion: March 2015
Last Updated: October 11, 2014
Last Verified: October 2014